Bausch Health Companies (BHC) vs Immunome (IMNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immunome (IMNM) has outperformed Bausch Health Companies (BHC) over the past year, gaining 38.2% versus a loss of 3.8%. Over five years, IMNM leads with a +8.4% price change compared with -78.4% for BHC. Bausch Health Companies is the larger company by market cap ($2.30 billion vs $2.25 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | IMNM |
|---|---|---|
| Share price | $6.15 | $19.10 |
| Market cap | $2.30B | $2.25B |
| 1-day change | +2.16% | -1.11% |
| YTD return | -11.51% | -11.10% |
| 1-year return | -3.76% | +38.17% |
| 5-year return | -78.41% | +8.43% |
| Forward P/E | 1.47 | — |
| EPS (TTM) | $-2.95 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.00 | $30.06 |
| 52-week low | $4.33 | $13.49 |
| Distance from 52-week high | -23.12% | -36.48% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +21.95% | +84.34% |
| Average volume | 3.26M | 1.19M |
| Shares outstanding | 373.99M | 118.00M |
| Employees | 20,300 | 247 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMNM has outperformed BHC by 41.9 percentage points over the past year.
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
BHC vs IMNM FAQ
Which is bigger, Bausch Health Companies or Immunome?
Bausch Health Companies (BHC) is larger, with a market capitalization of $2.30B compared with $2.25B for Immunome (IMNM).
Which stock has performed better over the past year, BHC or IMNM?
IMNM returned +38.17% over the past 12 months, compared with -3.76% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Immunome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.